Selected Publication

28.11.2016

Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data

Team 'A Bavarian Dream': From left to right: Donna Pauler Ankerst, Norbert Krautenbacher, Michael Laimighofer, Christoph Kurz, Christiane Fuchs, Hagen Scherb, Ivan Kondofersky, Julia Söllner; not pictured: Philip Dargatz (source: HMGU)

The goal of the Prostate Cancer DREAM Challenge initiative was to improve efficacy and toxicity predictions for a certain treatment used in prostate cancer patients. The outcome is now published in The Lancet Oncology indicating that joint analysis of scientific data with researchers from different fields can lead to gains in knowledge. The principle behind this type of teamwork is called "The Wisdom of Crowds". In this particular case, interdisciplinary cooperation led to the discovery that a biomarker (aspartate aminotransferase) that had previously received little attention makes an important contribution to the prognosis for prostate cancer. The newly developed model can better assess a patient's risk. Patients will profit from individual adaptation of the treatment.

A team of the ICB Research Group Biostatistics, led by Dr. Christiane Fuchs, was part of the DREAM Challenge and among the winners as "A Bavarian Dream" comprising researchers from the ICB, the Institute of Health Economics and Health Care Management (IGM), the Technical University of Munich, and the Johannes Wesling Hospital in Minden, Germany.


For more information see the original publication.
Justin Guinney et al (2016): Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data; Lancet Oncology. DOI: 10.1016/S1470-2045(16)30560-5    
and the press release by the Helmholtz Zentrum.